Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup
ARQT stock shows high growth momentum with 128% EPS growth, strong technicals, and breakout setup. Analyst targets imply upside. Discover the screen.
ChartMill16 days agoARQT
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals
Arcutis Biotherapeutics (ARQT) fits Louis Navellier's 8 growth rules—strong earnings, sales, margins, cash flow, and ROE.
ChartMill21 days agoARQT
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup
ARCUTIS Biotherapeutics (ARQT) shows strong growth with 76% revenue jump, solid technical setup near resistance, making it a compelling breakout candidate.
ChartMill24 days agoARQT
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
Benzinga29 days agoARQT
Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Arcutis Biotherapeutics, Inc.
SeekingAlpha29 days agoARQT
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.
Yahoo29 days agoARQT
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q2 2026 earnings call
Yahoo29 days agoARQT
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Benzinga29 days agoARQT
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
Benzinga29 days agoARQT